Although the molecular mechanism of SC-1 action needs to be further clarified, our data strongly suggest that SC-1 inhibits IL-6 production and will provide additional benefit in the management of the disease, which prevents tumor cells resistant to the TGFβ’s tumor suppression activity in cancers. This evidence concerns the gene TGFB1 and neoplasm.